Long-term all-cause mortality and its association with cardiovascular risk factors in thyroid cancer survivors: an Israeli population-based study.
Cardiovascular risk factors
Mortality
Thyroid cancer
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
17 Sep 2020
17 Sep 2020
Historique:
received:
27
06
2020
accepted:
13
09
2020
entrez:
18
9
2020
pubmed:
19
9
2020
medline:
23
4
2021
Statut:
epublish
Résumé
The global incidence of thyroid cancer (TC) has risen considerably during the last three decades, while prognosis is generally favorable. We assessed the long-term all-cause mortality in TC survivors compared to the general population, and its association with cardiovascular risk factors. Individuals diagnosed with TC during 2001-2014 (TC group) and age- and sex-matched individuals from the same Israeli healthcare system without thyroid disease or a cancer history (non-TC group) were compared. Cox regression hazard ratios (HRs) and 95% confidence intervals (95%CIs) for all-cause mortality were calculated by exposure status. During a 15-year follow-up (median 8 years), 577 TC survivors out of 5677 (10.2%) TC patients and 1235 individuals out of 23,962 (5.2%) non-TC patients died. The TC survivors had an increased risk of all-cause mortality (HR = 1.89, 95%CI 1.71-2.10), after adjusting for cardiovascular risk factors already present at follow-up initiation. This increased risk was most pronounced in the 55- to 64-year-old age group (HR = 1.49, 95%CI 1.33-1.67). The TC survivors who died by study closure had more hypertension (14.6% vs. 10.3%, P = 0.002), more dyslipidemia (11.4% vs. 7.2%, P < 0.001), and more cardiovascular disease (33.6% vs. 22.3%, P = 0.05) compared to those who died in the non-TC group. This large cohort study showed higher all-cause mortality with a higher prevalence of hypertension, dyslipidemia, and cardiovascular disease among TC survivors compared to matched non-TC individuals. Primary and secondary prevention of cardiovascular risk factors in TC survivors is mandatory.
Sections du résumé
BACKGROUND
BACKGROUND
The global incidence of thyroid cancer (TC) has risen considerably during the last three decades, while prognosis is generally favorable. We assessed the long-term all-cause mortality in TC survivors compared to the general population, and its association with cardiovascular risk factors.
METHODS
METHODS
Individuals diagnosed with TC during 2001-2014 (TC group) and age- and sex-matched individuals from the same Israeli healthcare system without thyroid disease or a cancer history (non-TC group) were compared. Cox regression hazard ratios (HRs) and 95% confidence intervals (95%CIs) for all-cause mortality were calculated by exposure status.
RESULTS
RESULTS
During a 15-year follow-up (median 8 years), 577 TC survivors out of 5677 (10.2%) TC patients and 1235 individuals out of 23,962 (5.2%) non-TC patients died. The TC survivors had an increased risk of all-cause mortality (HR = 1.89, 95%CI 1.71-2.10), after adjusting for cardiovascular risk factors already present at follow-up initiation. This increased risk was most pronounced in the 55- to 64-year-old age group (HR = 1.49, 95%CI 1.33-1.67). The TC survivors who died by study closure had more hypertension (14.6% vs. 10.3%, P = 0.002), more dyslipidemia (11.4% vs. 7.2%, P < 0.001), and more cardiovascular disease (33.6% vs. 22.3%, P = 0.05) compared to those who died in the non-TC group.
CONCLUSIONS
CONCLUSIONS
This large cohort study showed higher all-cause mortality with a higher prevalence of hypertension, dyslipidemia, and cardiovascular disease among TC survivors compared to matched non-TC individuals. Primary and secondary prevention of cardiovascular risk factors in TC survivors is mandatory.
Identifiants
pubmed: 32942995
doi: 10.1186/s12885-020-07401-3
pii: 10.1186/s12885-020-07401-3
pmc: PMC7500542
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
892Références
Endocrine. 2016 Aug;53(2):512-9
pubmed: 26860516
Int J Endocrinol. 2016;2016:9570171
pubmed: 27118971
Clin Endocrinol (Oxf). 2015 Jul;83(1):117-23
pubmed: 25115234
Clin Endocrinol (Oxf). 2011 Nov;75(5):709-14
pubmed: 21645022
JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):317-22
pubmed: 24557566
J Clin Endocrinol Metab. 2011 May;96(5):1344-51
pubmed: 21346066
Thyroid. 2011 May;21(5):471-6
pubmed: 21417919
Clin Endocrinol (Oxf). 2006 Apr;64(4):450-5
pubmed: 16584519
J Clin Endocrinol Metab. 2006 Aug;91(8):2892-9
pubmed: 16684830
J Clin Endocrinol Metab. 2008 Feb;93(2):504-15
pubmed: 18029468
Am J Epidemiol. 2010 Jan 15;171(2):242-52
pubmed: 19951937
Clin Invest Med. 2012 Jun 01;35(3):E152-6
pubmed: 22673318
J Clin Oncol. 2013 Feb 1;31(4):468-74
pubmed: 23270002
J Clin Oncol. 2013 Nov 10;31(32):4046-53
pubmed: 24101052
Thyroid. 2016 Mar;26(3):373-80
pubmed: 26914539
Int J Cancer. 2015 May 1;136(9):2187-95
pubmed: 25284703
Clin Cancer Res. 2016 Mar 1;22(5):1111-9
pubmed: 26490305
Thyroid. 2017 Jun;27(6):793-801
pubmed: 28338430
Arch Intern Med. 2012 May 28;172(10):799-809
pubmed: 22529182
J Endocrinol Invest. 2015 Feb;38(2):133-42
pubmed: 25194423
J Clin Endocrinol Metab. 2004 Sep;89(9):4469-73
pubmed: 15356049
PLoS One. 2014 Jul 09;9(7):e101527
pubmed: 25007092
N Engl J Med. 2014 Nov 6;371(19):1765-7
pubmed: 25372084
Endocr Metab Immune Disord Drug Targets. 2013 Mar;13(1):4-12
pubmed: 23369133
Ann Oncol. 2009 Oct;20(10):1728-35
pubmed: 19773250
Am J Otolaryngol. 2015 Jul-Aug;36(4):535-41
pubmed: 25794786
Acta Oncol. 2016;55(3):365-9
pubmed: 26541091
Thyroid. 2015 Oct;25(10):1106-14
pubmed: 26148759
Endocr Connect. 2019 Apr;8(4):398-406
pubmed: 30865929
J Clin Endocrinol Metab. 2014 Jul;99(7):2372-82
pubmed: 24654753
PLoS One. 2013;8(1):e55179
pubmed: 23383099
Cancer. 2011 Oct 1;117(19):4439-46
pubmed: 21432843
JAMA. 2017 Apr 4;317(13):1338-1348
pubmed: 28362912
Psychosom Med. 2007 Jun;69(5):410-4
pubmed: 17585062
J Clin Endocrinol Metab. 2013 Jan;98(1):172-80
pubmed: 23150687
World J Surg. 2016 Mar;40(3):538-44
pubmed: 26560150
Am J Epidemiol. 2016 Jun 15;183(12):1098-106
pubmed: 27257115
Thyroid. 2006 Apr;16(4):381-6
pubmed: 16646685
J Clin Endocrinol Metab. 2000 Jan;85(1):159-64
pubmed: 10634380
Int J Endocrinol. 2016;2016:9846790
pubmed: 27418929